Johnson & Johnson has announced its plans to acquire Neostrata, its affiliates and Tristrata Incorporated.
The acquisition enables Johnson & Johnson and Neostrata to discover and develop new important skincare solutions associated with human insights and compelling science.
DNA2.0 has announced its plans to develop protein pharmaceutical research by employing unparalleled antibody production and engineering platform through acquisition of MIGS’s assets.
Pursuant to the transaction, Michael Feldhaus, the co-founder of MIGS, will join DNA2.0 team as senior vice-president of antibody technologies in Newark, California.
Image: Johnson & Johnson has announced its plans to acquire Neostrata; Photo: courtesy of Luis Gracia.
Share this article
